secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095097
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atossa reports $79.5M cash, no debt; EVANGELINE Phase 2 40mg cohort shows 100% disease control rate
--------------------------------------------------------------------------------

- Ended Q2 2024 with $79.5M cash and cash equivalents, no debt; interest income $1.1M in Q2.
- Total operating expenses $7.1M in Q2 2024 vs $7.8M in Q2 2023, down 9% YoY.
- Phase 2 EVANGELINE 40mg cohort achieved 100% disease control rate at 24 weeks for ER+/HER2- breast cancer.
- Completed enrollment in EVANGELINE 80mg PK run-in cohort and dosing in Phase 2 Karisma-Endoxifen trial (240 patients).
- Appointed Heather Rees as CFO; joined Russell 3000 Index effective June 28, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024095097/0000950170-24-095097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000095017024095097/atos-20240812.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer